Investment Thesis
While Stereotaxis demonstrates exceptional 6375% revenue growth and healthy 60.3% gross margins indicating strong unit economics, the company is operationally unviable with -$6.0M operating losses on $6.3M revenue and negative operating cash flow of -$3.4M. At current burn rates, existing cash provides only ~4 years of runway with no clear near-term path to profitability, presenting significant execution risk despite minimal leverage.
Strengths
- Explosive revenue growth trajectory (6375% YoY) from minimal historical baseline suggests successful product launch or major commercial breakthrough
- Strong gross margins at 60.3% demonstrating attractive unit economics and pricing power for electromedical devices
- Fortress balance sheet with minimal debt (0.02x D/E ratio, only $243.6K long-term debt) and adequate liquidity (1.56x current ratio)
Risks
- Severe operating loss of -$6.0M on $6.3M revenue indicates operating expense structure is fundamentally misaligned with current scale
- Negative operating cash flow of -$3.4M is unsustainable; existing $14.6M cash provides only ~4 years runway without profitability inflection
- Revenue growth from near-zero base raises sustainability concerns; scale required to reach breakeven unclear and likely requires significant capital or major revenue acceleration
Key Metrics to Watch
- Operating cash flow trajectory and path to cash-flow breakeven
- Revenue growth sustainability and magnitude of next quarters versus 6375% base effect
- Operating expense leverage: whether opex grows slower than revenue as scale increases
Financial Metrics
Revenue
6.3M
Net Income
-5.9M
EPS (Diluted)
$-0.06
Free Cash Flow
-3.5M
Total Assets
54.0M
Cash
14.6M
Profitability Ratios
Gross Margin
60.3%
Operating Margin
-95.1%
Net Margin
-93.2%
ROE
-40.8%
ROA
-10.8%
FCF Margin
-56.0%
Balance Sheet & Liquidity
Current Ratio
1.56x
Quick Ratio
1.11x
Debt/Equity
0.02x
Debt/Assets
63.7%
Interest Coverage
N/A
Long-term Debt
243.6K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:15:56.520506 |
Data as of: 2026-03-31 |
Powered by Claude AI